SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
All News
Advertisement
Advertisement
Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.
Your daily dose of clinical news you may have missed.
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.
Your daily dose of clinical news you may have missed.
Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.
Primary care clinicians should screen all adults for the 3 mental health conditions to ensure timely referral for appropriate treatment.
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Advertisement
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Listen to 2 obesity experts discuss and analyze the role of insulin resistance in type 2 diabetes and obesity.
Your daily dose of clinical news you may have missed.
ENDO 2023. Women with PCOS face an increased risk of mortality, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS.
Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.
ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.
ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.
The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.
Acknowledging the historical harm caused by sole reliance on the measure for decisions in clinical practice, the AMA urges clinicians to incorporate other valid measures.
Your daily dose of clinical news you may have missed.
Advertisement
Advertisement
Advertisement